Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02773212 · ClinicalTrials.gov registry record · Phase 2
Targeting Anhedonia in Cocaine Use Disorder
A Phase 2 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT02773212 is a Phase 2 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 57 participants.
The verdict
NCT02773212, a Phase 2 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to examine anhedonia as a potential moderator of treatment outcomes for Cocaine Use Disorder (CUD). Specifically, this study will investigate how anhedonia affects outcomes in contingency management (CM) treatment for CUD and whether anhedonia mediates the effects of adjunctive treatment with a dopaminergic (DAergic) drug, d-amphetamine, on outcomes in CM for CUD, as well as investigate the contribution of anhedonia to overall CUD severity.
Interventions
- BEHAVIORAL Contingency management
- DRUG d-amphetamine
- DRUG Placebo (for d-amphetamine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2022-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02773212
The ClinicalTrials.gov registry entry for NCT02773212 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Contingency management is the first listed.
NCT02773212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02773212 about?
NCT02773212 is a clinical study titled "Targeting Anhedonia in Cocaine Use Disorder". The purpose of this study is to examine anhedonia as a potential moderator of treatment outcomes for Cocaine Use Disorder (CUD). Specifically, this study will investigate how anhedonia affects outcomes in contingency management (CM) treatment for CUD and whether anhedonia mediates the effects of adj...
What is the current status of trial NCT02773212?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2017-02-01. Estimated completion is 2022-04-04.
What interventions are being tested in trial NCT02773212?
The interventions under investigation include: Contingency management (BEHAVIORAL), d-amphetamine (DRUG), Placebo (for d-amphetamine) (DRUG).
Who is sponsoring clinical trial NCT02773212?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.